MedTrace Logo

Autologous Transplantation of BM-ECs With Platelet-Rich Plasma Extract for the Treatment of Critical Limb Ischemia

NCT02993809 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-12-15

No results posted yet for this study

Summary

The intent of this clinical study is to evaluate the safety of the injection composed of autologous bone marrow derived endothelial cells (BM-ECs) and platelet-rich plasma extract (PRPE) for the treatment of critical limb ischemia.

Conditions

  • Leg Ulcer
  • Diabetic Foot
  • Gangrene
  • Peripheral Vascular Disease
  • Ischemia

Interventions

BIOLOGICAL

BM-ECs and PRPE

BIOLOGICAL

BM-ECs

Sponsors & Collaborators

  • South China Research Center for Stem Cell and Regenerative Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-31
Primary Completion
2019-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02993809 on ClinicalTrials.gov